Nonalcoholic Fatty Liver Disease progresses to HCC in the absence of apparent Cirrhosis

Ertle, Judith; Dechêne, Alexander; Sowa, Jan; Penndorf, Volker; Herzer, Kerstin; Kaiser, Gernot; Schlaak, JF; Gerken, G; Canbay, Ali

doi:10.1055/s-0030-1269537

Cited by 24 publications

(30 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings were replicated in a European study of HCC and chronic liver disease, with 41.7% of HCC secondary to NASH occurring in patients without cirrhosis. This was in contrast to alcoholic liver disease, where 95% of HCC occurred in the setting of cirrhosis in this study (426). Without specific recommendations for NASH, patients found to have advanced fibrosis or cirrhosis should have an ultrasound and an ␣-fetoprotein measurement every 6 -12 months (425).…”

Section: Monitoring For Complications Of Liver Disease In Patienmentioning

confidence: 70%

Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo

et al. 2012

View full text Add to dashboard Cite

Recent data increasingly support a complex interplay between the metabolic condition diabetes mellitus and the pathologically defined nonalcoholic fatty liver disease (NAFLD). NAFLD predicts the development of type 2 diabetes and vice versa, and each condition may serve as a progression factor for the other. Although the association of diabetes and NAFLD is likely to be partly the result of a "common soil," it is also probable that diabetes interacts with NAFLD through specific pathogenic mechanisms. In particular, through interrelated metabolic pathways currently only partly understood, diabetes appears to accelerate the progression of NAFLD to nonalcoholic steatohepatitis, defined by the presence of necroinflammation, with varying degrees of liver fibrosis. In the research setting, obstacles that have made the identification of clinically significant NAFLD, and particularly nonalcoholic steatohepatitis, difficult are being addressed with the use of new imaging techniques combined with risk algorithms derived from peripheral blood profiling. These techniques are likely to be used in the diabetes population in the near future. This review examines the pathogenic links between NAFLD and diabetes by exploring the epidemiological evidence in humans and also through newer animal models. Emerging technology to help screen noninvasively for differing pathological forms of NAFLD and the potential role of preventive and therapeutic approaches for NAFLD in the setting of diabetes are also examined.

show abstract

Section: Monitoring For Complications Of Liver Disease In Patienmentioning

confidence: 70%

Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Several studies could recently dissect the effects of individual confounders of the metabolic syndrome and clearly demonstrate a significant risk for NAFLD patients to develop HCC [120]. Intriguingly, HCC in NAFLD not only arises from cirrhotic tissue; this might imply a special role for lipid metabolism and lipotoxicity in the carcinogenesis within this cohort [121].…”

Section: Liver Cancermentioning

confidence: 99%

The interaction of hepatic lipid and glucose metabolism in liver diseases

Bechmann

Hannivoort

Gerken

et al. 2012

Journal of Hepatology

805

604

View full text Add to dashboard Cite

It is widely known that the liver is a central organ in lipogenesis, gluconeogenesis and cholesterol metabolism. However, over the last decades, a variety of pathological conditions highlighted the importance of metabolic functions within the diseased liver. As observed in Western societies, an increase in the prevalence of obesity and the metabolic syndrome promotes pathophysiological changes that cause non-alcoholic fatty liver disease (NAFLD). NAFLD increases the susceptibility of the liver to acute liver injury and may lead to cirrhosis and hepatocellular cancer. Alterations in insulin response, β-oxidation, lipid storage and transport, autophagy and an imbalance in chemokines and nuclear receptor signaling are held accountable for these changes. Furthermore, recent studies revealed a role for lipid accumulation in inflammation and ER stress in the clinical context of liver regeneration and hepatic carcinogenesis. This review focuses on novel findings related to nuclear receptor signaling - including the vitamin D receptor and the liver receptor homolog 1 - in hepatic lipid and glucose uptake, storage and metabolism in the clinical context of NAFLD, liver regeneration, and cancer.

show abstract

“…Despite these limitations, similar findings were observed in another population-based case-control study which found that T2DM was associated with an almost threefold increase in the risk of HCC after adjusting for other major risk factors, including hepatitis C, hepatitis B, alcohol, and hemochromatosis (OR 2.87, CI 2.49–3.30) (Davila, Morgan, Shaib, McGlynn, & El-Serag, 2005). Furthermore, there is a growing number of case series and reports describing HCC associated with NASH in non-cirrhotic livers in the setting of T2DM and other metabolic components (Ertle et al, 2011; Guzman et al, 2008; Takuma & Nouso, 2010). This raises the important question of the need for regular surveillance in this population.…”

Section: Nafld In T2dmmentioning

confidence: 99%

Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes

Doycheva

Patel

Peterson

et al. 2013

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) frequently coexist due to shared risk factors. Their rising prevalence parallels the growing epidemic of obesity and insulin resistance (IR). In patients with T2DM and biopsy-proven NAFLD, a significantly higher prevalence of nonalcoholic steatohepatitis (NASH) (63–87%), any fibrosis (22–60%), and advanced fibrosis (4–9%) is noted. Possible risk factors for more advanced liver disease include concomitant metabolic syndrome with three or more components, visceral obesity, older age, increased duration of diabetes, and family history of diabetes. Liver biopsy is strongly suggested in these patients. Cardiovascular disease (CVD) and malignancy are the leading causes of death in this population, but a growing body of evidence shows liver-related mortality as an important cause of death, including an increased rate of hepatocellular carcinoma (HCC) in diabetes. The presence of NAFLD in T2DM is also associated with increased overall mortality. We aim with this review to summarize the results from studies investigating NAFLD in T2DM and to outline the factors that predict more advanced liver histology as well as the impact of these hepatic changes on CVD, overall and liver-related mortality.

show abstract

Nonalcoholic Fatty Liver Disease progresses to HCC in the absence of apparent Cirrhosis

Cited by 24 publications

References 0 publications

Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo

Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo

The interaction of hepatic lipid and glucose metabolism in liver diseases

Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes

Contact Info

Product

Resources

About